|
KMID : 0882420230980020059
|
|
Korean Journal of Medicine
2023 Volume.98 No. 2 p.59 ~ p.63
|
|
|
SGLT2 Inhibitors: Emerging Drugs in Heart Failure
|
|
Cho Dong-Hyuk
|
|
|
Abstract
|
|
|
|
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of diabetes medications that have demonstrated the potential to improve outcomes for heart failure (HF) patients. Although they were originally developed to treat diabetes, clinical trials have demonstrated their ability to both reduce the risk and improve the prognosis of HF. SGLT2 inhibitors have unique mechanisms of action, including improvement of water retention and promotion of lipolysis, which contribute to their effectiveness in treating HF. They are considered essential primary treatment options for patients with HF, regardless of diabetes status and ejection fraction. Overall, the use of SGLT2 inhibitors in patients with HF is expected to increase in the future and may further improve treatment outcomes for HF patients.
|
|
|
KEYWORD
|
|
|
Sodium-glucose transporter 2 inhibitors, Heart failure, Mechanism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|